Back to Search
OWEN O'CONNOR, M.D.
M.D.
Diagnostic Radiology Physician
NPI: 1609183201Individual
Specialties, Licenses & Credentials
Diagnostic Radiology PhysicianPrimary
Radiology — Diagnostic Radiology
Code: 2085R0202X
L-243708(MA)
Research & Publications (20)
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
PMID 19652067·J Clin Oncol·2009
3-trial
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
PMID 18691173·Br J Haematol·2008
3-trial
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
PMID 17910632·Br J Haematol·2007
3-trial
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
PMID 16675587·Clin Cancer Res·2006
7-preclinical
New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
PMID 17027659·Semin Hematol·2006
6-review
Pralatrexate: an emerging new agent with activity in T-cell lymphomas.
PMID 16988580·Curr Opin Oncol·2006
6-review
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
PMID 16330674·J Clin Oncol·2006
8-other
Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
PMID 16155030·J Clin Oncol·2005
4-observational
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
PMID 15613699·J Clin Oncol·2005
3-trial
Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches.
PMID 16019548·Leuk Lymphoma·2005
4-observational
The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
PMID 15233904·Curr Treat Options Oncol·2004
4-observational
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
PMID 19604235·Br J Haematol·2009
7-preclinical
A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients.
PMID 19373596·Leuk Lymphoma·2009
4-observational
Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.
PMID 19389878·Blood·2009
5-case
Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia.
PMID 19408055·Ann Surg Oncol·2009
5-case
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
PMID 19474785·Clin Pharmacol Ther·2009
8-other
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
PMID 19624539·Br J Haematol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- MASSACHUSETTS GENERAL HOSPITAL, 55 FRUIT STREET
BOSTON, MA 02114 - Phone
- (617) 726-8396
Quick Facts
- NPI
- 1609183201
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile